Fatal cutaneous strongyloidiasis as a side effect of pemphigus foliaceus treatment with mycophenolate mofetil

Journal of Drugs in Dermatology

Volumn 10, Issue 4, 2011, Pages 418-421

  Vitiello, Magalys ^b   Shelling, Michael ^a   Camacho, Ivan ^a   Milikowski, Clara ^a   Kerdel, Francisco A ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; HEMOGLOBIN; IVERMECTIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; DERMATOLOGICAL AGENT; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ABDOMINAL PAIN; AGED; ANAMNESIS; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; IMMUNOCOMPROMISED PATIENT; INTENSIVE CARE UNIT; LUNG INFILTRATE; MALE; NAUSEA; PAPULE; PEMPHIGUS FOLIACEUS; PURPURA; SEPTIC SHOCK; SKIN BIOPSY; SKIN DEFECT; SPUTUM CYTODIAGNOSIS; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; THORAX RADIOGRAPHY; ANIMAL; ETHNOLOGY; FATALITY; GUYANA; PEMPHIGUS; UNITED STATES;

AGED; ANIMALS; DERMATOLOGIC AGENTS; FATAL OUTCOME; GUYANA; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MYCOPHENOLIC ACID; PEMPHIGUS; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; UNITED STATES;

EID: 80052872795     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kazura JW. Nematode infections. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, PA: Saunders Elsevier; 2007.
2. Grove DI. Human Strongyloidiasis. Adv Parasitol. 1996;38:251-309. (Pubitemid 26289928)
3. Genta RM. Global prevalence of Strongyloidiasis: Critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis. 1989;11:755-767.
4. Jorgensen T, Montresor A, Savioli L. Effectively controlling Strongyloidiasis. [letter]. Parasitol Today. 1996;12:164.
5. Liu LX, Weller Pf. Strongyloidiasis and other intestinal nematode infections. Infect Dis Clin North Am. 1993;7:655-682. (Pubitemid 23298908)
6. Berk SL, Verghese A, Alvarez S, et al. Clinical and epidemiologic features of Strongyloidiasis. A prospective study in rural Tennessee. Arch Intern Med. 1987;147:1257-1261.
7. Miler MA, Church L W, Salgado CD. Strongyloides hyperinfection: A treatment dilemma. Am J Med Sci. 2008;336(4):358-361.
8. Gorman SR, Craven DE. Images in clinical medicine. Strongyloides stercoralis hyperinfection. N Engl J Med. 2008;359(11):e12.
9. Pacanowski J, Santos MD, Roux A. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: A case report. Am J Trop Med Hyg. 2005;73:122-124. (Pubitemid 41278760)
10. Fardet L, Genereau T, Poirot J-L, et al. Severe Strongyloidiasis in corticosteroid-treated patients: Case series and literature review. J Infect. 2006;54:18-27.
11. Concha R, Harrington W, Rogers A. Intestinal Strongyloidiasis: Recognition, management, and determinants of outcome. J Clin Gastroenterol. 2005;39:203-211. (Pubitemid 40283955)
12. Olsen A, Van Lieshout L, Marti H, et al. Strongyloidiasis - the most neglected of the neglected tropical diseases. Trans R Soc Trop Med Hyg. 2009;103(10):967-972.
13. Woodring JH, Halfhill H, Reed JC. Pulmonary Strongyloidiasis: Clinical and imaging features of pulmonary Strongyloidiasis. Am J Roentgenol. 1994;162:537-542. (Pubitemid 24093549)
14. Woodring JH, Halfhill H, Berger R, Reed JC, Moser N. Clinical and imaging features of pulmonary Strongyloidiasis. South Med J. 1996;89:10-19. (Pubitemid 26026703)
15. Genta RM. Strongyloides stercoralis. In: Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, eds. Infections of the gastrointestinal tract. New York: Raven Press; 1995:1197-1207.
16. Berk SL, Verghese A. Parasitic pneumonia. Semin Respir Infect. 1988;3:172-178.
17. Pinatelle P, De Monbrison F, Bedock B. Disseminated Strongyloidiasis with parasitemia in a patient under corticosteroid treatment. Med Mal Infect. 2009;39(4):267-269.
18. Genta RM. Strongyloidiasis. In: Guerrant R, Walker D, Weller P. editors. Essentials of tropical infectious diseases. Vol 1. New York: Churchill Livingstone; 2001:464-468.
19. Siddiqui A, Berk S. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis. 2001;33:1040-1047. (Pubitemid 32907108)
20. Tarr PE, Miele PS, Peregoy KS, et al. Case report: Rectal administration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg. 2003;68:4535.
21. Keiser P, Nutman T. Strongyloides stercoralis in the inmunocompromised population. Clin Microbiol Rev. 2004;17:208-217.
22. Link K, Orenstein R. Bacterial complications of Strongyloidiasis: Streptococcus bovis meningitis. South Med J. 1999;92:728-731. (Pubitemid 29334695)
23. Salluh J, Feres G, Velasco E, et al. Successful use of parenteral ivermectin in an immunosuppressed patient with disseminated Strongyloidiasis and septic shock. Intensive Care Med. 2005;31:1292. (Pubitemid 41355810)
24. Afzal A. Siddiqui and Steven L. Berk. Diagnosis of Strongyloides stercoralis infection. Clinical Infectious Diseases. 2001;33(7):1040-1047.
25. Orvis AK, Wesson SK, Breaza TS, et al. Mycophenolate Mofetil in dermatology. J Am Acad Dermatol. 2009;60(2):183-194.
26. Galimberti R, Ponton A, Zaputocich FA, et al. Disseminated strongyloidias in inmunocompromised patients - Report of three cases. Int J Dermatology. 2009;48(9):975-978.
27. Carvalho EM, Da Fonesca Porto A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol. 2004;26:487-497. (Pubitemid 40461165)
28. FDA ALERT [5/16/2008] - Inosine Monophosphate Dehydrogenase Inhibitors (IMPDH) Immunosuppressant. Mycophenolate Mofetil (marketed as CellCept) and Mycophenolic Acid (marketed as Myfortic) - Healthcare Professional Sheet text version.
29. Fulmer HS, Huempfner HR. Intestinal helminthes in eastern Kentucky: A survey in three rural counties. Am J Trop Med Hyg. 1965;14:269-275.